Advertisement
Advertisement
MESO
Mesoblast Limited - ADR
15.67
USDSponsored
+0.12
+0.77%
Apr 30, 16:00 UTC -4
Closed
After-Market
15.66
-0.01
-0.03%
MESO Earnings Reports
Positive Surprise Ratio
MESO beat 9 of 12 last estimates.
75%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Mesoblast Limited - ADR earnings per share and revenue
On Jan 29, 2026, MESO reported earnings of -0.03 USD per share (EPS) for Q2 26, beating the estimate of -0.15 USD, resulting in a 80.12% surprise. Revenue reached --, compared to an expected 52.52 million, with a --% difference. The market reacted with a -3.96% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kymera Therapeutics, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.89
Actual
-$0.71
Surprise
+21.05%
Syndax Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.48
Surprise
+19.15%
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.15%
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Biogen Inc. Common Stock
Report Date
Apr 29, 2026 For Q1 26
Estimate
$3.07
Actual
$3.57
Surprise
+16.28%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
Pacira BioSciences, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.57
Actual
$0.60
Surprise
+4.42%
FAQ
What were Mesoblast Limited - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Mesoblast Limited - ADR reported EPS of -$0.03, beating estimates by 80.12%, and revenue of --, -- -- expectations.
How did the market react to Mesoblast Limited - ADR's Q2 2026 earnings?
The stock price moved down -3.96%, changed from $18.70 before the earnings release to $17.96 the day after.
When is Mesoblast Limited - ADR expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Mesoblast Limited - ADR's next earnings report?
Based on --
analysts, Mesoblast Limited - ADR is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement